Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Proteogenomic Subtyping of Chronic Lymphocytic Leukemia Identifies a Novel Poor Outcome Subgroup with a Distinct Drug Response Profile

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-137528

Published: 2020

Journal Articles

Prognostic Impact of Immunohistochemistry and MRD Results in Bone Marrow after Frontline Chemoimmunotherapy of Chronic Lymphocytic Leukemia (CLL): Results of Central Laboratory Analyses of the CLL10 Trial of the German CLL Study Group (GCLLSG)

Blood (2017) 130 (Supplement 1): 3021.

https://doi.org/10.1182/blood.V130.Suppl_1.3021.3021

Published: 2017

Journal Articles

Subset-Specific Recurrence of Mutations and Identification of Functional Modules Provides New Clues about the Pathogenesis of Large Granular Lymphocyte Leukemia

Alessandro Coppe, BSc, PhD, Emma I Andersson, MSc, Andrea Binatti, BSc, Vanessa R Gasparini, Sabrina Bortoluzzi, Michael J. Clemente, M.S., Marco Herling, MD PhD, Jaroslaw P. Maciejewski, MD, PhD, FACP, Satu Mustjoki, MD PhD, Stefania Bortoluzzi, BSc, PhD

Blood (2016) 128 (22): 4117.

https://doi.org/10.1182/blood.V128.22.4117.4117

Published: 2016

Journal Articles

BKV Disease during the First 100 Days after Allogeneic Hematopoietic Stem Cell Transplantation - Results of a Screening Program and Retrospective Analysis

Philip Posdzich, Marco Herling, MD PhD, Silke Leitzke, Laura Hamacher, Veronica Di Christanziano, MD, Konstantin Hoeller, Rolf Kaiser, MD PhD, Jens Chemnitz, MD, Christof Scheid, MD PhD, Udo Holtick, MD PhD

Blood (2016) 128 (22): 3403.

https://doi.org/10.1182/blood.V128.22.3403.3403

Published: 2016

Journal Articles

Transformation of Chronic Lymphocytic Leukemia Towards Richter´s Syndrome Is Induced By AKT Activation

Nadine Nickel, PhD, Mona Al-Maarri, Martin Pal, Andreas Roth, Gero Knittel, Carmen D. Herling, MD PhD, Nina Reinart, PhD, Stephan Schäfer, MD, Elena M Hartmann, Andreas Rosenwald, MD, Wolfram Klapper, MD, Reinhard Büttner, Marco Herling, MD PhD, Jens Bruening, Christian Reinhardt, Michael Hallek, Thomas Wunderlich, PhD, Christian Pallasch, MD

Blood (2016) 128 (22): 2031.

https://doi.org/10.1182/blood.V128.22.2031.2031

Published: 2016

Journal Articles

Favorable Toxicity Profile and Long Term Outcome of Elderly, but Physically Fit CLL Patients (pts) Receiving First Line Bendamustine and Rituximab (BR) Frontline Chemoimmunotherapy in Comparison to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Advanced Chronic Lymphocytic Leukemia (CLL): Update Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)

Blood (2016) 128 (22): 4382.

https://doi.org/10.1182/blood.V128.22.4382.4382

Published: 2016

Journal Articles

Novel Mutations in NOTCH and Altered Wnt/β-Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia

Henan Zhang, MD, Shulan Tian, Esteban Braggio, PhD, Andrew L Feldman, MD, Rhett P. Ketterling, MD, Rong He, MD, Timothy G. Call, MD, Thomas E. Witzig, MD, Sameer A. Parikh, MD, Yi Lin, MD PhD, Charla R Secreto, Emma I Andersson, MSc, Satu Mustjoki, MD PhD, Alexandra Schrader, Marco Herling, MD PhD, Huihuang Yan, Ph. D, Wei Ding, MD PhD

Blood (2016) 128 (22): 4103.

https://doi.org/10.1182/blood.V128.22.4103.4103

Published: 2016

Journal Articles

Human CD21 low CD86 pos B Cells Are Potent Antigen Presenting Cells, Which Are Expanded in Inflammatory Conditions

Alexander Shimabukuro-Vornhagen, MD, María Alejandra García-Márquez, PhD, Rieke N. Fischer, Juliane Iltgen-Breburda, Anne Fiedler, Kerstin Wennhold, PhD, Gunter Rappl, Hinrich Abken, Pia Hartmann, Clara Lehmann, Thomas Koslowsky, Marco Herling, MD, Dirk Beutner, Dominik Wolf, MD, Gerd Fätkenheuer, Andrea Rubbert-Roth, Michael Hallek, MD, Sebastian Theurich, Michael von Bergwelt-Baildon, Prof. Dr. Dr.

Blood (2015) 126 (23): 3432.

https://doi.org/10.1182/blood.V126.23.3432.3432

Published: 2015

Journal Articles

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Emma I Andersson, MSc, Shady Adnan, MD MSc, Leopold Sellner, MD, Dorine Bellanger, Alexandra Schrader, Giuliano Crispatzu, Henan Zhang, MD, Carlos C Mateos, PhD, Edgar Faber, MD PhD, Steffen Koschmieder, MD, Tim H. Brummendorf, MD PhD, Krister Wennerberg, PhD, Wei Ding, MD PhD, Marc-Henri Stern, MD PhD, Marco Herling, MD, Simon Anders, PhD, Wolfgang Huber, PhD, Thorsten Zenz, MD, Satu Mustjoki, MD, PhD

Blood (2015) 126 (23): 315.

https://doi.org/10.1182/blood.V126.23.315.315

Published: 2015

Journal Articles

Induction Treatment with Alemtuzumab Combined with Polychemotherapy Containing Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) Followed By Alemtuzumab Maintenance in Patients with T-Cell Prolymphocytic Leukaemia (T-PLL): First Analysis of a Prospective Multicenter Phase-II-Trial (T-PLL2) Conducted By the German CLL Study Group (GCLLSG)

Natali Pflug, MD, Georg Hopfinger, MD, Paula Cramer, MD, Alexandra Schrader, PhD, Nicole Weit, PhD, Rita Meister, Miriam Thiel, Tanja Annolleck, Anne Westermann, Till M Seiler, MD, Thorsten Zenz, MD, Jan Duerig, MD, Jasmin Bahlo, Karl-Anton Kreuzer, MD, Stephan Stilgenbauer, MD, Anna-Maria Fink, MD, Barbara Eichhorst, MD, Michael Hallek, MD, Marco Herling, MD

Blood (2014) 124 (21): 1999.

https://doi.org/10.1182/blood.V124.21.1999.1999

Published: 2014

Journal Articles

MCL-1 Critically Regulates Survival Of T-Lymphocyte Non-Hodgkin Lymphoma

Sabine Spinner, Kelly Gemma, PhD, Marco Herold, PhD, Konstanze Pechloff, PhD, Giuliano Crispatzu, Jürgen Ruland, MD, Marco Herling, MD, Christian Peschel, MD, Andreas Strasser, PhD, Philipp J. Jost, MD

Blood (2013) 122 (21): 4246.

https://doi.org/10.1182/blood.V122.21.4246.4246

Published: 2013

Journal Articles

High T-Cell Lymphoma Breakpoint 1 (TCL1) Levels Are Associated with Lack of Response and Inferior Outcome Following Fludarabine, Cyclophosphamide, Rituximab (FCR) Frontline Therapy in Patients with Chronic Lymphocytic Leukemia (CLL).

Ellen Schlette, MD, Constantine S. Tam, MB.BS, Marco Herling, MD, Carlos Bueso-Ramos, MD, PhD, William Wierda, MD, Alessandra Ferrajoli, MD, Susan O’Brien, MD, Michael Keating, MB.BS, Dan Jones

Blood (2008) 112 (11): 2086.

https://doi.org/10.1182/blood.V112.11.2086.2086

Published: 2008

Journal Articles

Upregulation of the Chemokine Receptor CCR4 in Cutaneous T-Cell Lymphoma and Nodal T-Cell Lymphoma: Implications for Targeted Therapy.

Dan Jones, MD, PhD, Kaushali Patel, MS, Marco Herling, MD, Richard J. Aguilar, Ryuzo Ueda, MD, PhD, Hiroshi Inagaki, MD, Luis Fayad, MD, Madeleine Duvic, MD

Blood (2004) 104 (11): 2646.

https://doi.org/10.1182/blood.V104.11.2646.2646

Published: 2004

Journal Articles

TCL1 Expression in B-Cell Tumors Is Dynamically Regulated by Maturation Stage, Proliferation, and the Follicular Microenvironment.

Marco Herling, MD, Ryuji Kobayashi, PhD, Kaushali A. Patel, MS, Kong Chao Chang, MD, Ellen Schlette, MD, George Z. Rassidakis, MD, L. Jeffrey Medeiros, MD, Dan Jones, MD, PhD

Blood (2004) 104 (11): 4333.

https://doi.org/10.1182/blood.V104.11.4333.4333

Published: 2004

NARROW

Proteogenomic Subtyping of Chronic Lymphocytic Leukemia Identifies a Novel Poor Outcome Subgroup with a Distinct Drug Response Profile

Prognostic Impact of Immunohistochemistry and MRD Results in Bone Marrow after Frontline Chemoimmunotherapy of Chronic Lymphocytic Leukemia (CLL): Results of Central Laboratory Analyses of the CLL10 Trial of the German CLL Study Group (GCLLSG)

Subset-Specific Recurrence of Mutations and Identification of Functional Modules Provides New Clues about the Pathogenesis of Large Granular Lymphocyte Leukemia

BKV Disease during the First 100 Days after Allogeneic Hematopoietic Stem Cell Transplantation - Results of a Screening Program and Retrospective Analysis

Transformation of Chronic Lymphocytic Leukemia Towards Richter´s Syndrome Is Induced By AKT Activation

Novel Mutations in NOTCH and Altered Wnt/β-Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia

Human CD21 low CD86 pos B Cells Are Potent Antigen Presenting Cells, Which Are Expanded in Inflammatory Conditions

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

MCL-1 Critically Regulates Survival Of T-Lymphocyte Non-Hodgkin Lymphoma

High T-Cell Lymphoma Breakpoint 1 (TCL1) Levels Are Associated with Lack of Response and Inferior Outcome Following Fludarabine, Cyclophosphamide, Rituximab (FCR) Frontline Therapy in Patients with Chronic Lymphocytic Leukemia (CLL).

Upregulation of the Chemokine Receptor CCR4 in Cutaneous T-Cell Lymphoma and Nodal T-Cell Lymphoma: Implications for Targeted Therapy.

TCL1 Expression in B-Cell Tumors Is Dynamically Regulated by Maturation Stage, Proliferation, and the Follicular Microenvironment.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only